ELV icon

Elevance Health

389.22 USD
+3.93
1.02%
At close Jan 21, 4:00 PM EST
After hours
386.01
-3.21
0.82%
1 day
1.02%
5 days
-0.49%
1 month
4.94%
3 months
-7.82%
6 months
-22.76%
Year to date
6.39%
1 year
-17.51%
5 years
27.20%
10 years
178.65%
 

About: Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.

Employees: 104,900

0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

12% more repeat investments, than reductions

Existing positions increased: 661 | Existing positions reduced: 591

2% more first-time investments, than exits

New positions opened: 134 | Existing positions closed: 131

4% less call options, than puts

Call options by funds: $634M | Put options by funds: $660M

1% less funds holding

Funds holding: 1,677 [Q2] → 1,658 (-19) [Q3]

3.37% less ownership

Funds ownership: 91.71% [Q2] → 88.34% (-3.37%) [Q3]

4% less funds holding in top 10

Funds holding in top 10: 52 [Q2] → 50 (-2) [Q3]

8% less capital invested

Capital invested by funds: $115B [Q2] → $106B (-$9.58B) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$480
23%
upside
Avg. target
$506
30%
upside
High target
$551
42%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Truist Securities
David Macdonald
57% 1-year accuracy
55 / 96 met price target
23%upside
$480
Buy
Maintained
6 Jan 2025
Mizuho
Ann Hynes
36% 1-year accuracy
8 / 22 met price target
30%upside
$505
Outperform
Maintained
5 Nov 2024
Wells Fargo
Stephen Baxter
24% 1-year accuracy
9 / 38 met price target
27%upside
$495
Overweight
Maintained
4 Nov 2024
Morgan Stanley
Erin Wright
43% 1-year accuracy
10 / 23 met price target
42%upside
$551
Overweight
Maintained
23 Oct 2024
Barclays
Andrew Mok
30% 1-year accuracy
19 / 63 met price target
29%upside
$501
Overweight
Maintained
22 Oct 2024

Financial journalist opinion

Based on 7 articles about ELV published over the past 30 days

Neutral
Business Wire
9 hours ago
Mark Farrah Associates Delves into Acquisition Impacts Utilizing New Tools
CANONSBURG, Pa.--(BUSINESS WIRE)--MFA reviewed Elevance Health's acquisition of Indiana University Health Plans using Medicare Benefits Analyzer and County Health Coverage.
Mark Farrah Associates Delves into Acquisition Impacts Utilizing New Tools
Positive
Zacks Investment Research
1 day ago
Elevance Health Q4 Countdown: Smart Move to Buy or Stick With Hold?
ELV's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Elevance Health Q4 Countdown: Smart Move to Buy or Stick With Hold?
Positive
Zacks Investment Research
4 days ago
Unveiling Elevance Health (ELV) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Elevance Health (ELV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Unveiling Elevance Health (ELV) Q4 Outlook: Wall Street Estimates for Key Metrics
Neutral
Business Wire
1 week ago
Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2024 Results on January 23, 2025
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release fourth quarter and full year 2024 financial results on January 23, 2025, at 6:00 a.m. Eastern Standard Time (“EST”). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (Inte.
Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2024 Results on January 23, 2025
Neutral
Zacks Investment Research
2 weeks ago
Healthcare Executives Bullish on 2025: But Why Are Stocks Slipping?
Improving the consumer experience, engagement and trust is emerging as a top strategy for healthcare companies.
Healthcare Executives Bullish on 2025: But Why Are Stocks Slipping?
Positive
Seeking Alpha
2 weeks ago
My Top 15 High Growth Dividend Stocks For January 2025
The SPDR S&P 500 ETF Trust ended 2024 on a sour note, losing 2.41% in December and finishing the year up 24.89%. The Top 15 dividend growth stocks for January 2025 offer an average dividend yield of 1.21% and appear to be about 27% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.33% compound annual growth rate.
My Top 15 High Growth Dividend Stocks For January 2025
Neutral
Seeking Alpha
3 weeks ago
Elevance Health Is An Undervalued Healthcare Juggernaut
Elevance Health is a strong buy despite a 30% stock decline, due to its solid fundamentals and market position in the health insurance industry. The company benefits from secular trends like an aging population and increased life expectancy, driving long-term demand for healthcare services. Key risks include rising healthcare costs and a shrinking Medicaid member base, impacting margins and free cash flow.
Elevance Health Is An Undervalued Healthcare Juggernaut
Neutral
Zacks Investment Research
1 month ago
Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?
ELV is reallocating resources to more profitable areas and making prudent acquisitions.
Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?
Positive
Seeking Alpha
1 month ago
Santa's Stunning Stocking Surprises: 5 High Yield Blue-Chip Bargains For 2025
Investing in blue-chip stocks at 52-week lows can potentially yield significant returns if fundamentals are strong. Avoid value traps by focusing on companies with solid fundamentals, like Elevance Health, Becton, Dickinson, LyondellBasell, Rogers Communications and Rexford Industrial Realty. These companies offer a 3.7% yield and a 27% discount to fair value, and they have historically outperformed the market with 27% less volatility.
Santa's Stunning Stocking Surprises: 5 High Yield Blue-Chip Bargains For 2025
Neutral
GlobeNewsWire
1 month ago
Robbins LLP Informs Elevance Health Inc. Stockholders that it is Investigating the Officers and Directors of ELV to Determine if They Breached Fiduciary Duties Owed to Shareholders
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Elevance Health Inc. (NASDAQ: ELV) to determine whether certain Elevance officers and directors violated securities laws and breached fiduciary duties to shareholders. Elevance is a healthcare company that supports consumers, families, and communities across the entire care journey.
Robbins LLP Informs Elevance Health Inc. Stockholders that it is Investigating the Officers and Directors of ELV to Determine if They Breached Fiduciary Duties Owed to Shareholders
Charts implemented using Lightweight Charts™